How can we improve the assessment of safety in child and adolescent psychopharmacology?

How can we improve the assessment of safety in child and adolescent psychopharmacology?

Item
http://www.wikidata.org/entity/Q35200957
Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based studyDopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.Practitioner review: adolescent alcohol use disorders: assessment and treatment issues.Pediatric psychotropic polypharmacySuicidal ideation reports from pediatric trials for paroxetine and venlafaxine.Treatment for Adolescents with Depression Study (TADS): safety resultsTolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.Evidence review and clinical guidance for the use of ziprasidone in Canada.The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents.The child and adolescent psychiatry trials network (CAPTN): infrastructure development and lessons learned.Psychotropic medication monitoring checklists: use and utility for children in residential care.A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns.Benefits exceed risks of newer antidepressant medications in youth--maybe.A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials.
P2860

How can we improve the assessment of safety in child and adolescent psychopharmacology?

Item
http://www.wikidata.org/entity/Q35200957
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@ast
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@en
type
label
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@ast
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@en
prefLabel
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@ast
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
How can we improve the assessment of safety in child and adolescent psychopharmacology?
@en
P2093
P304
P31
P356
10.1097/01.CHI.0000046840.90931.36
P433
P478
P50
P577
P698
P921